Alvotech ALVO Stock Price Today, Quote & News

High institutional ownership can be a signal of strong market trust in this company. In the past three months, Alvotech insiders have not sold or bought any company stock. Alvotech has only been the subject of 1 research reports in the past 90 days. Provide specific products and services to you, such as portfolio management or data aggregation. Style is an investment factor that has a meaningful impact on investment risk and returns.

growing your money in bank savings accounts Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Alvotech’s shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.

Alvotech SA (ALVO)

It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas https://1investing.in/ inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira . AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara . It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an «uptick» in price and the value of trades made on a «downtick» in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades.

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of ALVO stock can currently be purchased for approximately $9.80.

Stock Activity

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. The Company is focused on the development and manufacture of biosimilar medicines for patients globally.

A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALVO, but not buy additional shares or sell existing shares. 4 equities research analysts have issued 12 month price targets for Alvotech’s stock. On average, they expect the company’s stock price to reach $12.00 in the next year. This suggests a possible upside of 22.4% from the stock’s current price. View analysts price targets for ALVO or view top-rated stocks among Wall Street analysts. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Analyst rating

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Price and EPS Surprise Chart

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

Style is calculated by combining value and growth scores, which are first individually calculated. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.

The company’s average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

• We’d like to share more about how we work and what drives our day-to-day business.
• The Company is focused on the development and manufacture of biosimilar medicines for patients globally.
• Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33.
• Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.
• © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
• There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. Alvotech SA share price live 9.80, this page displays NASDAQ ALVO stock exchange data. View the ALVO premarket stock price ahead of the market session or assess the after hours quote.

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

Alvotech shares are trading lower after the FDA issued a complete response letter for the company’s AVT02 BLA. Get MarketBeat All Access Free for 30 DaysJoin thousands of other investors who make better investing decisions with our premium tools. Access advanced stock screeners, portfolio monitoring tools, proprietary research reports, and more.

Dow Jones Network

To see all exchange delays and terms of use please see Barchart’s disclaimer. Alvotech’s stock was trading at $10.00 at the start of the year. Since then, ALVO stock has decreased by 2.0% and is now trading at $9.80. According to analysts’ consensus price target of $12.00, Alvotech has a forecasted upside of 22.4% from its current price of $9.80. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year. These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. LOS ANGELES—-Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Alvotech (“Alvote… NEW YORK—- #A–Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Alvotech (“Alvotech” or the “Company”) (NASD… Real-time analyst ratings, insider transactions, earnings data, and more.